Does the media prefer DSGN or CHRS?

In the previous week, Design Therapeutics and Design Therapeutics both had 1 articles in the media. Design Therapeutics' average media sentiment score of 0.67 beat Coherus Oncology's score of 0.00 indicating that Design Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Design Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Coherus Oncology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer CADL or CHRS?

In the previous week, Candel Therapeutics and Candel Therapeutics both had 1 articles in the media. Candel Therapeutics' average media sentiment score of 0.50 beat Coherus Oncology's score of 0.00 indicating that Candel Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Candel Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Coherus Oncology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer CLYM or CHRS?

In the previous week, Climb Bio had 6 more articles in the media than Coherus Oncology. MarketBeat recorded 7 mentions for Climb Bio and 1 mentions for Coherus Oncology. Climb Bio's average media sentiment score of 0.68 beat Coherus Oncology's score of 0.00 indicating that Climb Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Climb Bio 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Coherus Oncology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ACRS or CHRS?

In the previous week, Aclaris Therapeutics had 1 more articles in the media than Coherus Oncology. MarketBeat recorded 2 mentions for Aclaris Therapeutics and 1 mentions for Coherus Oncology. Aclaris Therapeutics' average media sentiment score of 0.33 beat Coherus Oncology's score of 0.00 indicating that Aclaris Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aclaris Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Coherus Oncology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor CHRS or PHAR?

In the previous week, Pharming Group had 13 more articles in the media than Coherus Oncology. MarketBeat recorded 14 mentions for Pharming Group and 1 mentions for Coherus Oncology. Pharming Group's average media sentiment score of 0.34 beat Coherus Oncology's score of 0.00 indicating that Pharming Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coherus Oncology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pharming Group 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Coherus Oncology (CHRS) Competitors

$1.35 +0.12 (+9.76%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.31 -0.04 (-2.96%)

As of 09/18/2026 07:35 PM Eastern

Compare

CHRS vs. DSGN, CADL, CLYM, ACRS, and PHAR

Should you buy Coherus Oncology stock or one of its competitors? Coherus Oncology's main competitors and comparable companies include Design Therapeutics (DSGN), Candel Therapeutics (CADL), Climb Bio (CLYM), Aclaris Therapeutics (ACRS), and Pharming Group (PHAR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Coherus Oncology compare to Design Therapeutics?

Design Therapeutics (NASDAQ:DSGN) and Coherus Oncology (NASDAQ:CHRS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations.

Design Therapeutics has a net margin of 0.00% compared to Coherus Oncology's net margin of -259.41%. Design Therapeutics' return on equity of -34.03% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Design Therapeutics	N/A	-34.03%	-32.05%
Coherus Oncology	-259.41%	-222.75%	-52.11%

Design Therapeutics has a beta of 1.66, meaning that its stock price is 66% more volatile than the broader market. Comparatively, Coherus Oncology has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market.

56.6% of Design Therapeutics shares are owned by institutional investors. Comparatively, 72.8% of Coherus Oncology shares are owned by institutional investors. 17.1% of Design Therapeutics shares are owned by insiders. Comparatively, 7.2% of Coherus Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Design Therapeutics presently has a consensus target price of $16.50, indicating a potential upside of 34.80%. Coherus Oncology has a consensus target price of $11.00, indicating a potential upside of 714.81%. Given Coherus Oncology's higher possible upside, analysts plainly believe Coherus Oncology is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Coherus Oncology has higher revenue and earnings than Design Therapeutics. Design Therapeutics is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Design Therapeutics	N/A	N/A	-$69.79M	-$1.18	N/A
Coherus Oncology	$42.17M	4.95	$168.02M	-$1.03	N/A

In the previous week, Design Therapeutics and Design Therapeutics both had 1 articles in the media. Design Therapeutics' average media sentiment score of 0.67 beat Coherus Oncology's score of 0.00 indicating that Design Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Design Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Coherus Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Design Therapeutics beats Coherus Oncology on 9 of the 15 factors compared between the two stocks.

How does Coherus Oncology compare to Candel Therapeutics?

Candel Therapeutics (NASDAQ:CADL) and Coherus Oncology (NASDAQ:CHRS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

13.9% of Candel Therapeutics shares are owned by institutional investors. Comparatively, 72.8% of Coherus Oncology shares are owned by institutional investors. 14.3% of Candel Therapeutics shares are owned by company insiders. Comparatively, 7.2% of Coherus Oncology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Candel Therapeutics and Candel Therapeutics both had 1 articles in the media. Candel Therapeutics' average media sentiment score of 0.50 beat Coherus Oncology's score of 0.00 indicating that Candel Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Candel Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Coherus Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Candel Therapeutics has a beta of -0.48, indicating that its stock price is 148% less volatile than the broader market. Comparatively, Coherus Oncology has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market.

Candel Therapeutics currently has a consensus price target of $19.29, indicating a potential upside of 77.99%. Coherus Oncology has a consensus price target of $11.00, indicating a potential upside of 714.81%. Given Coherus Oncology's stronger consensus rating and higher probable upside, analysts clearly believe Coherus Oncology is more favorable than Candel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Candel Therapeutics has a net margin of 0.00% compared to Coherus Oncology's net margin of -259.41%. Candel Therapeutics' return on equity of -76.98% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Candel Therapeutics	N/A	-76.98%	-48.50%
Coherus Oncology	-259.41%	-222.75%	-52.11%

Coherus Oncology has higher revenue and earnings than Candel Therapeutics. Candel Therapeutics is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Candel Therapeutics	N/A	N/A	-$38.18M	-$1.41	N/A
Coherus Oncology	$42.17M	4.95	$168.02M	-$1.03	N/A

Summary

Coherus Oncology beats Candel Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Coherus Oncology compare to Climb Bio?

Climb Bio (NASDAQ:CLYM) and Coherus Oncology (NASDAQ:CHRS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and valuation.

Climb Bio currently has a consensus price target of $26.92, indicating a potential upside of 91.62%. Coherus Oncology has a consensus price target of $11.00, indicating a potential upside of 714.81%. Given Coherus Oncology's higher probable upside, analysts plainly believe Coherus Oncology is more favorable than Climb Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	3.00
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Coherus Oncology has higher revenue and earnings than Climb Bio. Climb Bio is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Climb Bio	N/A	N/A	-$59.85M	-$0.83	N/A
Coherus Oncology	$42.17M	4.95	$168.02M	-$1.03	N/A

In the previous week, Climb Bio had 6 more articles in the media than Coherus Oncology. MarketBeat recorded 7 mentions for Climb Bio and 1 mentions for Coherus Oncology. Climb Bio's average media sentiment score of 0.68 beat Coherus Oncology's score of 0.00 indicating that Climb Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Climb Bio	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Coherus Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

69.8% of Climb Bio shares are owned by institutional investors. Comparatively, 72.8% of Coherus Oncology shares are owned by institutional investors. 2.6% of Climb Bio shares are owned by insiders. Comparatively, 7.2% of Coherus Oncology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Climb Bio has a beta of 0.09, meaning that its stock price is 91% less volatile than the broader market. Comparatively, Coherus Oncology has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market.

Climb Bio has a net margin of 0.00% compared to Coherus Oncology's net margin of -259.41%. Climb Bio's return on equity of -31.79% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Climb Bio	N/A	-31.79%	-30.79%
Coherus Oncology	-259.41%	-222.75%	-52.11%

Summary

Climb Bio beats Coherus Oncology on 9 of the 16 factors compared between the two stocks.

How does Coherus Oncology compare to Aclaris Therapeutics?

Aclaris Therapeutics (NASDAQ:ACRS) and Coherus Oncology (NASDAQ:CHRS) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, media sentiment, analyst recommendations and risk.

Aclaris Therapeutics currently has a consensus price target of $11.33, suggesting a potential upside of 106.06%. Coherus Oncology has a consensus price target of $11.00, suggesting a potential upside of 714.81%. Given Coherus Oncology's higher probable upside, analysts clearly believe Coherus Oncology is more favorable than Aclaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	3.11
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Aclaris Therapeutics has a beta of 0.79, indicating that its stock price is 21% less volatile than the broader market. Comparatively, Coherus Oncology has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market.

In the previous week, Aclaris Therapeutics had 1 more articles in the media than Coherus Oncology. MarketBeat recorded 2 mentions for Aclaris Therapeutics and 1 mentions for Coherus Oncology. Aclaris Therapeutics' average media sentiment score of 0.33 beat Coherus Oncology's score of 0.00 indicating that Aclaris Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aclaris Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Coherus Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Coherus Oncology has higher revenue and earnings than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclaris Therapeutics	$8.22M	93.57	-$64.92M	-$0.58	N/A
Coherus Oncology	$42.17M	4.95	$168.02M	-$1.03	N/A

98.3% of Aclaris Therapeutics shares are owned by institutional investors. Comparatively, 72.8% of Coherus Oncology shares are owned by institutional investors. 4.8% of Aclaris Therapeutics shares are owned by company insiders. Comparatively, 7.2% of Coherus Oncology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Coherus Oncology has a net margin of -259.41% compared to Aclaris Therapeutics' net margin of -921.50%. Aclaris Therapeutics' return on equity of -61.65% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclaris Therapeutics	-921.50%	-61.65%	-42.41%
Coherus Oncology	-259.41%	-222.75%	-52.11%

Summary

Aclaris Therapeutics beats Coherus Oncology on 10 of the 17 factors compared between the two stocks.

How does Coherus Oncology compare to Pharming Group?

Coherus Oncology (NASDAQ:CHRS) and Pharming Group (NASDAQ:PHAR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk.

Coherus Oncology has higher earnings, but lower revenue than Pharming Group. Coherus Oncology is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coherus Oncology	$42.17M	4.95	$168.02M	-$1.03	N/A
Pharming Group	$376.13M	1.99	$2.85M	$0.12	87.92

In the previous week, Pharming Group had 13 more articles in the media than Coherus Oncology. MarketBeat recorded 14 mentions for Pharming Group and 1 mentions for Coherus Oncology. Pharming Group's average media sentiment score of 0.34 beat Coherus Oncology's score of 0.00 indicating that Pharming Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Coherus Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pharming Group	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

72.8% of Coherus Oncology shares are owned by institutional investors. Comparatively, 0.0% of Pharming Group shares are owned by institutional investors. 7.2% of Coherus Oncology shares are owned by company insiders. Comparatively, 2.1% of Pharming Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Coherus Oncology has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market. Comparatively, Pharming Group has a beta of 0.01, meaning that its stock price is 99% less volatile than the broader market.

Coherus Oncology currently has a consensus target price of $11.00, indicating a potential upside of 714.81%. Pharming Group has a consensus target price of $38.67, indicating a potential upside of 266.51%. Given Coherus Oncology's stronger consensus rating and higher possible upside, analysts clearly believe Coherus Oncology is more favorable than Pharming Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Pharming Group	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Pharming Group has a net margin of 2.51% compared to Coherus Oncology's net margin of -259.41%. Pharming Group's return on equity of 3.40% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coherus Oncology	-259.41%	-222.75%	-52.11%
Pharming Group	2.51%	3.40%	1.90%

Summary

Pharming Group beats Coherus Oncology on 9 of the 16 factors compared between the two stocks.

Get Coherus Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CHRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CHRS vs. The Competition

Export

Metric	Coherus Oncology	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$208.58M	$3.88B	$7.24B	$12.95B
Dividend Yield	N/A	3.64%	2.57%	12.80%
P/E Ratio	-1.31	14.23	275.49	25.40
Price / Sales	4.95	1,434.96	642.70	86.83
Price / Cash	N/A	108.90	76.25	51.42
Price / Book	2.70	15.45	10.46	6.33
Net Income	$168.02M	-$22.86M	$3.49B	$358.33M
7 Day Performance	1.50%	-1.21%	0.59%	1.12%
1 Month Performance	2.27%	-3.29%	-1.74%	-2.39%
1 Year Performance	-16.15%	37.74%	18.13%	5.35%

Coherus Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CHRS Coherus Oncology	1.6135 of 5 stars	$1.35 +9.8%	$11.00 +714.8%	-16.1%	$208.58M	$42.17M	N/A	144	Gap Up High Trading Volume
DSGN Design Therapeutics	2.6128 of 5 stars	$12.87 -4.8%	$16.50 +28.3%	+102.3%	$812.00M	N/A	N/A	55	Positive News
CADL Candel Therapeutics	3.2883 of 5 stars	$10.54 -1.3%	$19.29 +82.9%	+125.3%	$808.50M	N/A	N/A	55
CLYM Climb Bio	3.499 of 5 stars	$13.85 -4.9%	$26.92 +94.5%	+508.2%	$799.57M	N/A	N/A	29	Analyst Upgrade Insider Trade
ACRS Aclaris Therapeutics	2.1418 of 5 stars	$5.45 -3.4%	$11.33 +108.1%	+188.0%	$765.51M	$7.83M	N/A	73

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CHRS) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Coherus Oncology (CHRS) Competitors

CHRS vs. DSGN, CADL, CLYM, ACRS, and PHAR

How does Coherus Oncology compare to Design Therapeutics?

Summary

How does Coherus Oncology compare to Candel Therapeutics?

Summary

How does Coherus Oncology compare to Climb Bio?

Summary

How does Coherus Oncology compare to Aclaris Therapeutics?

Summary

How does Coherus Oncology compare to Pharming Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CHRS vs. The Competition

Coherus Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Coherus Oncology (CHRS) Competitors

CHRS vs. DSGN, CADL, CLYM, ACRS, and PHAR

How does Coherus Oncology compare to Design Therapeutics?

Is DSGN or CHRS more profitable?

Which has more volatility and risk, DSGN or CHRS?

Do institutionals & insiders believe in DSGN or CHRS?

Do analysts prefer DSGN or CHRS?

Which has preferable valuation and earnings, DSGN or CHRS?

Does the media prefer DSGN or CHRS?

Summary

How does Coherus Oncology compare to Candel Therapeutics?

Do insiders & institutionals believe in CADL or CHRS?

Does the media prefer CADL or CHRS?

Which has more volatility & risk, CADL or CHRS?

Do analysts recommend CADL or CHRS?

Is CADL or CHRS more profitable?

Which has better earnings & valuation, CADL or CHRS?

Summary

How does Coherus Oncology compare to Climb Bio?

Do analysts rate CLYM or CHRS?

Which has preferable earnings & valuation, CLYM or CHRS?

Does the media prefer CLYM or CHRS?

Do insiders and institutionals believe in CLYM or CHRS?

Which has more volatility and risk, CLYM or CHRS?

Is CLYM or CHRS more profitable?

Summary

How does Coherus Oncology compare to Aclaris Therapeutics?

Do analysts prefer ACRS or CHRS?

Which has more risk & volatility, ACRS or CHRS?

Does the media prefer ACRS or CHRS?

Which has stronger earnings and valuation, ACRS or CHRS?

Do insiders & institutionals have more ownership in ACRS or CHRS?

Is ACRS or CHRS more profitable?

Summary

How does Coherus Oncology compare to Pharming Group?

Which has stronger valuation & earnings, CHRS or PHAR?

Does the media favor CHRS or PHAR?

Do insiders & institutionals believe in CHRS or PHAR?

Which has more volatility & risk, CHRS or PHAR?

Do analysts recommend CHRS or PHAR?

Is CHRS or PHAR more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CHRS vs. The Competition

Coherus Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools